|
Feto Maternal and GenetYX Center
pbpk feto maternal models ![]() Pbpk Feto Maternal Models, supplied by Feto Maternal and GenetYX Center, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/maternal+pbpk+model/pbpk+feto+maternal+models/pmc05824116-136-3-4 Average 90 stars, based on 1 article reviews
pbpk feto maternal models - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Simcyp
maternal–fetal physiologically based pharmacokinetic (pbpk) model for sublingual buprenorphine ![]() Maternal–Fetal Physiologically Based Pharmacokinetic (Pbpk) Model For Sublingual Buprenorphine, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/maternal+pbpk+model/maternal+fetal+physiologically+based+pharmacokinetic++pbpk++model+for+sublingual+buprenorphine/pmc10975492-2-16-21 Average 90 stars, based on 1 article reviews
maternal–fetal physiologically based pharmacokinetic (pbpk) model for sublingual buprenorphine - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Simcyp
maternal fetal pbpk model in simcyp ![]() Maternal Fetal Pbpk Model In Simcyp, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/maternal+pbpk+model/fetal+in+maternal+model+pbpk+simcyp/pmc13136160-89-11-15 Average 86 stars, based on 1 article reviews
maternal fetal pbpk model in simcyp - by Bioz Stars,
2026-11
86/100 stars
|
Buy from Supplier |
Image Search Results
Journal: CPT: Pharmacometrics & Systems Pharmacology
Article Title: Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations
doi: 10.1002/psp4.12274
Figure Lengend Snippet: The best practice approach to physiologically based pharmacokinetic (PBPK) model development and application in pregnant women. ADME, absorption, distribution, metabolism, and excretion; DDI, drug‐to‐drug interaction; PK, pharmacokinetic.
Article Snippet: We believe that
Techniques:
Journal: CPT: Pharmacometrics & Systems Pharmacology
Article Title: Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations
doi: 10.1002/psp4.12274
Figure Lengend Snippet: A mechanistic framework for applying a physiologically based pharmacokinetic (PBPK) feto‐maternal model for predicting human fetotoxicity risk from preclinical species described in the following steps. (1) Perform fetotoxicity studies in preclinical animals and establish exposure‐toxicity relationships. (2) Construct a coupled feto‐maternal PBPK model that accounts for gestational age related changes in the physiology and placenta to describe the relationship between fetal tissue and systemic concentrations together with maternal systemic concentration. (3) Use the constructed PBPK model to find the toxic doses that can cause feto‐toxic drug levels after accounting for species differences in physiological/biochemical parameters (number of placentas, weight, blood flow, transporters, and enzyme expression). (4) The human PBPK model can also be refined if in vitro and/or in vivo human data are available. (5) The human PBPK model that predicts the systemic exposure in fetus and mother can be used to predict the local fetal tissue concentration. (6) Fetal local tissue concentration can be linked to the predicted toxicity after accounting for any potential species differences in the toxicodynamic model. This figure is adapted from the publication by Abduljalil et al . Conc, concentration; IC50, half‐maximal inhibitory concentration.
Article Snippet: We believe that
Techniques: Construct, Concentration Assay, Expressing, In Vitro, In Vivo
Journal: Pharmaceutics
Article Title: Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling
doi: 10.3390/pharmaceutics16030375
Figure Lengend Snippet: Maternal–fetal physiologically based pharmacokinetic (PBPK) model-based predicted and observed maternal buprenorphine plasma concentrations during the ( a ) second trimester, ( b ) third trimester, and ( c ) postpartum period. Pregnant subjects received 8 mg buprenorphine twice daily as sublingual tablets. Blue solid line and shaded area represent the mean concentration–time profile and 5th to 95th percentile range of the virtual population (n = 100), respectively. Open blue circles represent concentration–time data reported by Zhang et al. [ , ].
Article Snippet: To allow the conceptualization of fetal buprenorphine exposure, a maternal–fetal physiologically based pharmacokinetic (PBPK) model for
Techniques: Clinical Proteomics, Concentration Assay
Journal: Pharmaceutics
Article Title: Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling
doi: 10.3390/pharmaceutics16030375
Figure Lengend Snippet: Individual maternal–fetal physiologically based pharmacokinetic (PBPK) model-based predicted and observed maternal and fetal buprenorphine plasma concentrations at delivery. Pregnant women received between 1 and 28 mg buprenorphine daily as sublingual tablets, and individual doses are shown in the lower left corner of each figure subsection. Closed red circles represent observed buprenorphine concentrations in maternal and umbilical cord blood reported by ( a – j ) Bartu et al. and ( k – u ) Wiegand et al. for a total of 21 mother–fetus dyads. Simulated concentration–time profiles with 5th to 95th population percentile ranges (n = 100 mother–fetus dyads) were created either under the presumption that the proportion of the administered dose sublingually absorbed by the expectant mother equals 0.754 × (38.1 − 19.7 × log (Dose)), which is the default absorption extent in the maternal–fetal PBPK model for sublingual tablets (shown in blue and green for maternal and fetal concentrations, respectively), or with the degree of maternal sublingual absorption optimized (across a range of 0.1–99.9%) post hoc to capture the reported maternal concentration–time point as accurately as possible (shown in grayscale). The final degrees of sublingual absorption are shown in the upper right corner of each figure subsection (written in blue and gray to reflect the model’s default and optimized value, respectively).
Article Snippet: To allow the conceptualization of fetal buprenorphine exposure, a maternal–fetal physiologically based pharmacokinetic (PBPK) model for
Techniques: Clinical Proteomics, Concentration Assay
Journal: Pharmaceutics
Article Title: Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling
doi: 10.3390/pharmaceutics16030375
Figure Lengend Snippet: Mean maternal–fetal physiologically based pharmacokinetic (PBPK) model-based predicted maternal (aged 18–45 years) and umbilical cord blood concentrations of buprenorphine early in the second trimester, at the end of the second trimester, and at the end of the third trimester (15, 27, and 40 weeks’ gestational age, respectively) following a standard 16 mg buprenorphine dose as sublingual tablet. The concentration–time curves are juxtaposed with the expected profile of a nonpregnant woman under the same conditions (created using the previously developed base model) .
Article Snippet: To allow the conceptualization of fetal buprenorphine exposure, a maternal–fetal physiologically based pharmacokinetic (PBPK) model for
Techniques: Concentration Assay
Journal: Pharmaceutics
Article Title: Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling
doi: 10.3390/pharmaceutics16030375
Figure Lengend Snippet: Goodness-of-fit plots for the maternal–fetal physiologically based pharmacokinetic (PBPK) model for buprenorphine, showing ( a , b ) predicted vs. observed maternal and ( c , d ) fetal concentrations following administration of buprenorphine sublingual tablets. Coefficients of determination ( R 2 ) and associated p values are shown in the lower right corner of each figure subset. Concentrations were predicted either ( a , c ) under the presumption that the proportion of the administered dose sublingually absorbed by the expectant mother equals 0.754 × (38.1 − 19.7 × log (Dose)), which is the default absorption extent in the maternal–fetal PBPK model for sublingual tablets, or ( b , d ) with the degree of maternal sublingual absorption optimized (across a range of 0.1–99.9%) post hoc to capture the reported maternal concentration–time point as accurately as possible. Blue circles (●) and green diamonds (◆) represent maternal and fetal concentration–time data reported by Bartu et al. and Wiegand et al. , respectively. Dotted lines represent the 2-fold prediction error range. Curved dashed lines represent locally estimated scatterplot smoothing (LOESS) curves.
Article Snippet: To allow the conceptualization of fetal buprenorphine exposure, a maternal–fetal physiologically based pharmacokinetic (PBPK) model for
Techniques: Concentration Assay
Journal: Pharmaceutics
Article Title: Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling
doi: 10.3390/pharmaceutics16030375
Figure Lengend Snippet: Goodness-of-fit plots for the maternal–fetal physiologically based pharmacokinetic (PBPK) model for buprenorphine, showing ( a , b ) dose vs. the ratio between maternal predicted and observed concentrations (concentration fold-difference) and ( c , d ) dose vs. fetal concentration fold-differences. Concentrations were predicted either ( a , c ) under the presumption that the proportion of the administered dose sublingually absorbed by the expectant mother equals 0.754 × (38.1 − 19.7 × log (Dose)), which is the default absorption extent in the maternal–fetal PBPK model for sublingual tablets, or ( b , d ) with the degree of maternal sublingual absorption optimized (across a range of 0.1–99.9%) post hoc to capture the reported maternal concentration–time point as accurately as possible. Blue circles (●) and green diamonds (◆) represent concentration fold-differences obtained from maternal and fetal concentration–time data reported by Bartu et al. and Wiegand et al. , respectively. Dotted lines represent the 2-fold prediction error range. Curved dashed lines represent locally estimated scatterplot smoothing (LOESS) curves.
Article Snippet: To allow the conceptualization of fetal buprenorphine exposure, a maternal–fetal physiologically based pharmacokinetic (PBPK) model for
Techniques: Concentration Assay